226 related articles for article (PubMed ID: 8978794)
1. [Methotrexate-leucovorin rescue therapy: pharmacological characteristics and clinical effective use].
Fujimoto T
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1901-6. PubMed ID: 8978794
[TBL] [Abstract][Full Text] [Related]
2. "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment.
Bertino JR
Semin Oncol; 1977 Jun; 4(2):203-16. PubMed ID: 301662
[No Abstract] [Full Text] [Related]
3. "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.
Von Hoff DD; Rozencweig M; Louie AC; Bender RA; Muggia FM
Cancer Treat Rep; 1978 Feb; 62(2):233-5. PubMed ID: 305823
[No Abstract] [Full Text] [Related]
4. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
[TBL] [Abstract][Full Text] [Related]
5. High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how?
Sterba J; Valík D; Bajciová V; Kadlecová V; Gregorová V; Mendelová D
Neoplasma; 2005; 52(6):456-63. PubMed ID: 16284689
[TBL] [Abstract][Full Text] [Related]
6. [Controlled ultra-high dosage methotrexate therapy in three patients with metastatic osteosarcoma (author's transl)].
Leber H; Kotz R; Chiari K; Endler T; Gabl F; Krisch K; Salzer-Kuntschik M
Wien Klin Wochenschr; 1981 Apr; 93(7):236-40. PubMed ID: 7020262
[TBL] [Abstract][Full Text] [Related]
7. The Memorial Sloan Kettering Cancer Center experience with outpatient administration of high dose methotrexate with leucovorin rescue.
Zelcer S; Kellick M; Wexler LH; Gorlick R; Meyers PA
Pediatr Blood Cancer; 2008 Jun; 50(6):1176-80. PubMed ID: 18266225
[TBL] [Abstract][Full Text] [Related]
8. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
[TBL] [Abstract][Full Text] [Related]
9. High-dose trimetrexate and minimal-dose leucovorin: a case for selective protection?
Hum M; Holcenberg JS; Tkaczewski I; Weaver JW; Wilson J; Kamen BA
Clin Cancer Res; 1998 Dec; 4(12):2981-4. PubMed ID: 9865909
[TBL] [Abstract][Full Text] [Related]
10. Understanding and managing methotrexate nephrotoxicity.
Widemann BC; Adamson PC
Oncologist; 2006 Jun; 11(6):694-703. PubMed ID: 16794248
[TBL] [Abstract][Full Text] [Related]
11. Treatment of refractory myositis: a randomized crossover study of two new cytotoxic regimens.
Villalba L; Hicks JE; Adams EM; Sherman JB; Gourley MF; Leff RL; Thornton BC; Burgess SH; Plotz PH; Miller FW
Arthritis Rheum; 1998 Mar; 41(3):392-9. PubMed ID: 9506565
[TBL] [Abstract][Full Text] [Related]
12. Systemic treatment options in advanced colorectal cancer: perspectives on combination 5-fluorouracil plus leucovorin.
Grem JL
Semin Oncol; 1997 Oct; 24(5 Suppl 18):S18-8-S18-18. PubMed ID: 9420016
[TBL] [Abstract][Full Text] [Related]
13. Progression of osteosarcoma after high-dose methotrexate: over-rescue by folinic acid.
Cohen IJ
Pediatr Hematol Oncol; 2003 Dec; 20(8):579-81. PubMed ID: 14578026
[TBL] [Abstract][Full Text] [Related]
14. Osteogenic sarcoma: state of the art with high-dose methotrexate treatment.
Jaffe N
Clin Orthop Relat Res; 1976 Oct; (120):95-102. PubMed ID: 1086179
[TBL] [Abstract][Full Text] [Related]
15. [Compatibility and toxicity of methotrexate in the treatment of bone tumors].
Pongracz N; Kelaridis T; Ritschl P
Arzneimittelforschung; 1987 Apr; 37(4):456-60. PubMed ID: 3496891
[TBL] [Abstract][Full Text] [Related]
16. Substitution of l-leucovorin for d,l-leucovorin in the rescue from high-dose methotrexate treatment in patients with osteosarcoma.
Jaffe N; Jorgensen K; Robertson R; George M; Letvak L; Barrett G
Anticancer Drugs; 1993 Oct; 4(5):559-64. PubMed ID: 8292813
[TBL] [Abstract][Full Text] [Related]
17. Advances in individual prediction of methotrexate toxicity: a review.
Schmiegelow K
Br J Haematol; 2009 Sep; 146(5):489-503. PubMed ID: 19538530
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
19. The classic: recent advances in chemotherapy of metastatic osteogenic sarcoma. 1972.
Jaffe N
Clin Orthop Relat Res; 2005 Sep; 438():19-21. PubMed ID: 16131864
[No Abstract] [Full Text] [Related]
20. Patient case involving high-dose methotrexate followed by leucovorin rescue.
Alsop JA
Am J Hosp Pharm; 1978 Feb; 35(2):127. PubMed ID: 305201
[No Abstract] [Full Text] [Related]
[Next] [New Search]
